Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
On May 22, 2017, Yasir B. Al-Wakeel, the Chief Financial Officer, Head of Corporate Development, Principal Accounting Officer and Treasurer of Merrimack Pharmaceuticals, Inc., provided notice of his resignation, effective as of June 9, 2017.
About Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. Its therapeutic oncology candidates in clinical development include MM-398, MM-302, MM-121, MM-141 and MM-151. Its ONIVYDE (irinotecan liposome injection), also known as MM-398, is an encapsulation of the marketed chemotherapy drug irinotecan in a liposomal formulation. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. MM-121 is a fully human monoclonal antibody that targets Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3). MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes. MM-151 is an oligoclonal therapeutic designed to bind to non-overlapping epitopes of EGFR (ErbB1). Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Recent Trading Information
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) closed its last trading session down -0.04 at 3.40 with 1,876,888 shares trading hands.
